How to Cite
Abstract
This literature review is devoted to the relationship of the structural features of the metabolic syndrome in proliferative processes and endometrial cancer (EC), and the identification of the relationship between the individual components of the metabolic syndrome and the development of endometrial cancer. The metabolic syndrome is currently a global medical and social problem, which is due to the wide spread of this symptom complex in the population. Today, the main concept of this syndrome is the concept of a cluster of components associated with an increased risk of developing type 2 diabetes and cardiovascular diseases. It is known that an increase in the mass of adipose tissue above the norm by 20% or more leads to dysfunction of the hypothalamic-pituitary-ovarian system. At the same time, the risk of RE on the background of metabolic syndrome increases by 2-3 times. This probability also largely depends on the severity of proliferation in the endometrium, which is caused by the presence of dyshormonal and metabolic disorders. In addition, this is due to the aggravation of insulin resistance, an increase in the production of androgens by the ovaries, the formation of stable anovulation and, as a result, the progression of pathological changes in the endometrium. With the onset of peri - and postmenopausal endometrial hyperplasia in about 50% of cases progressing to malignant pathology. The role of the system of insulin-like growth factors, adipokines secreted from visceral adipocytes of free fatty acids, local estrogen formation and hyperandrogenization is also recognized in creating a predisposition to the EC formation. According to the results of the study of the functioning of the autocrine-paracrine system of adipose tissue, the risk of endometrial proliferative processes is higher at low levels of adiponectin and high levels of insulin. All this indicates the feasibility of monitoring the status of adipose tissue.
References
Capasso I, Esposito Е, de Laurentiis M, et al. Metabolic syndrome breast cancer link varies by intrinsic molecular subtype. Diabetol Metab syndr. 2014; 6(1):105. DOI: 10.1186/1758-5996-6-105
Bhandari R, Kelley GA, Hartley TA, et al. Metabolic syndrome is associated with increased breast cancer risk: A systematic review with meta-analysis. Int J Breast Cancer. 2014; 2014:189384. DOI: 10.1155/2014/189384
Irem Kirac Utku, Yildiz okuturlar, Esra Demir, et al. Relationship between epicardial adipose tissue thickness and vitamin D in patients with metabolic syndrome. Int J Clin Exp Med. 2015; 8 (4): 5707-5714.
Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a system review and meta-analysis. Diabetes Care. 2012; 35 (11): 2402-11. DOI: 10.2337/dc12-0336
Yunusova NV, Kondakova IV, Kolomiets LA, et al. The role of metabolic syndrome variant in the malignant tumors progression. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2010. 10.1016/j. dsx.2018.04.028. DOI: 10.1016/j.dsx.2018.04.028
Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. Ann Oncol. 2011; 22(12):2687-92. mdr025. DOI: 10.1093/annonc/
Bj0rge T, Lukanova A, Jonsson H, et al. Metabolic syndrome and breast cancer in the me-can (metabolic syndrome and cancer) project. Cancer Epidemiol Biomarkers Prev. 2010; 19(7):1737-45. DOI: 10.1158/1055-9965.EPI-10-0230
Ulmer H, Bj0rge T, Concin H, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecol Oncol. 2012; 125(2):330-5. DOI: 10.1016/j.ygyno.2012.01.052
Nagel G, Concin H, Bj0rge Т, et al. Metabolic syndrome and rare gynecological cancers in the metabolic syndrome and cancer project (Me-Can). Annals of Oncology. 2011; 22(6):1339-1345. DOI: 10.1093/annonc/mdq597
Tawfik A, Bassma M, Elsabaa Dalia A, et al. The impact of metabolic syndrome on the clinical profile and tumor characteristics of endometrial carcinoma. J Reprod Contracept Obstet Gynecol. 2016; 5(11):3696-3703. DOI: 10.18203/2320-1770.ijrcog20163831
Глазкова О.Л., Топольская И.В., Подзолкова Н.М. Динамика метаболического синдрома у больных с железисто-кистозной гиперплазией эндометрия на фоне гормональной терапии//Актуальные вопросы акушерства и гинекологии: Сб. научных материалов. -2001-2002. -Т.1. -№1. -С.146-147.
Furukawa s, Fujita T, shimabukuro M. et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Investigation. 2004; 114(12):1752-176. DOI: 10.1172/JCI21625
Бутрова С.А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению//РМЖ. -2001. -Т.9. -№2. -С.56-62.
Макацария А.Д., Бицадзе В.О., Хизроева Д.Х. Применение низкомолекулярного гепарина при тромбо-филических состояниях в акушерской практике//Русский медицинский журнал. -2005. -Т.13. -№ 17. -С.130-138. [
Коломиец Л.А., Бочкарева Н.В., Чернышова А.Л. Рак эндометрия и метаболический синдром. -Томск: Изд-во «Иван Федоров», 2010.
Александровский Я.А. Молекулярные механизмы взаимовлияния патологических процессов при совместном протекании сахарного диабета и рака. Научные и клинические аспекты//Биохимия. -2002. -Т.67. -№12. -С.1611-1631.
Артымук Н.В. Молекулярно -генетические аспекты рака эндометрия у женщин с нейроэндокринными нарушениями//Сибирский онкологический журнал. -2007. -Приложения №1. -С.5-8.
Grundy SM, Cleeman JI, Daniels SR, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation.2005;112(17):2735-52. DOI: 10.1161/CIRCULATIONAHA.105.169404
Executive summary of the third report of the National Cholesterol Education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholestrol in adults (Adult Treatment Panel III)//JAMA; 2001.
Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-80. x. DOI: 10.1111/j.1464-5491.2006.01858
Bochkareva NV, Kolomiets LA, Kondakova IV. Enzymes of estrogen metabolism in endometrial cancer. Bulletin of Experimental Biology and Medicine Volume. 2006; 141(2): 240-242.
К.П. Лактионов, Л.О. Николаенко, А.И. Беришвили. Метаболический синдром и рак органов репродуктивной системы (обзор литературы).//Опухоли женской репродуктивной системы. -2014. -№2. -С56-58.
Л.М. Берштейн, И.В. Берлев, Д.А. Васильев и др. Ожирение и особенности рака эндометрия: меняется ли что-нибудь с годами?//Вопросы онкологии. -2015. -Т.61.-№4. -С 575-579
А.И. Беришвили, К.П. Лактионов, Т.М. Кочоян. Лапароскопические операции у больных раком тела матки с метаболическим синдромом. Онкология. Журнал им. П.А. Герцена. -2015.-Т.4-№3. -С 35-38.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019